

Appl. No. 10/053,302  
Amendment dated May 31, 2005  
Reply to Final Office Action February 28, 2005

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) An anti-IFNAR2 antibody selected from the group consisting of antibody 1F3 produced by a hybridoma with ATCC Accession No. HB 12426 or progeny thereof, antibody 3B7 produced by a hybridoma with ATCC Accession No. HB 12427 or progeny thereof, and antibody 1D3 produced by the hybridoma with ATCC Accession No. HB 12428 or progeny thereof.
2. (Original) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with the antibody of claim 1.
3. (Currently amended) A polypeptide comprising a portion of the antibody of claim 1 or 2, wherein said portion comprises an antigen binding fragment or a variable region of said antibody.
4. (Canceled)
5. (Original) The antibody of claim 2, wherein said antibody does not substantially block binding of a Type I interferon to IFNAR2.
6. (Original) The antibody of claim 5, wherein said Type I interferon is IFN $\alpha$ -2/1.
7. (Original) The antibody of claim 5, wherein said antibody blocks anti-viral activity of a first Type I interferon and does not block anti-viral activity of a second Type I interferon.

Appl. No. 10/053,302  
Amendment dated May 31, 2005  
Reply to Final Office Action February 28, 2005

8. (Previously presented) The antibody of claim 5, wherein said antibody competes for binding to IFNAR2 with antibody 1D3 produced by a hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

9. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a monoclonal antibody.

10. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a humanized antibody.

11. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a human antibody.

12-13. (Canceled)

14. (Previously presented) A composition comprising the antibody of claims 1-3 or 9-11 and an excipient.

15. (Previously presented) An anti-IFNAR2 antibody IF3 produced by a hybridoma with ATCC Accession No. HB 12426 or progeny thereof.

16. (Previously presented) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody IF3 produced by hybridoma with ATCC Accession No. HB 12426 or progeny thereof.

17. (Previously presented) An anti-IFNAR2 antibody 3B7 produced by a hybridoma with Accession No. HB 12427 or progeny thereof.

Appl. No. 10/053,302  
Amendment dated May 31, 2005  
Reply to Final Office Action February 28, 2005

18. (Previously presented) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody 3B7 produced by hybridoma with ATCC Accession No. HB 12427 or progeny thereof.

19. (Currently amended) An anti-IFNAR2 antibody 1D3 1D3 produced by a hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

20. (Currently amended) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody 1D3 1D3 produced by hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

21. (New) The antibody of claim 7, wherein the antibody blocks the activity of IFN- $\alpha$ 8, IFN- $\alpha$ 5, IFN- $\alpha$ 2, and IFN- $\alpha$ 1.

22. (New) The antibody of claim 21, wherein the second Type I interferon is IFN- $\beta$ .

23. (New) The antibody of claim 1, wherein the antibody blocks IGSF complex formation.